Intervention: Minocycline
Trial phase: Phase 2
ATC code: A01AB23 | D10AF07 | J01AA08 | J01AA20
SMILES: [H][C@@]12Cc3c(N(C)C)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: 100 mg orally every 12 hours
Eligibility criteria:
Inclusion Criteria:

HIV infected
Currently on a stable ART regimen for at least 16 consecutive weeks prior to study entry. Participants whose regimens have changed with respect to dose or formulation are eligible, but patients who have changed to different drugs in the same class are not eligible. Participants taking atazanavir must also be taking ritonavir or a ritonavir-boosted drug to be eligible for this study. More information on this criterion can be found in the protocol.
Plan to stay on current ART regimen between study screening and Week 24
AIDS Dementia Scale (ADC) Stage greater than 0
Cognitive impairment, as evidenced by neuropsychological tests administered at screening
Progressive neurocognitive decline. More information on this criterion can be found in the protocol.
Estimated premorbid IQ of 70 or higher indicated by an age-corrected scaled score of 5 or higher on the vocabulary section of the Wechsler Adult Intelligence Scale Revised (WAIS-R) administered at study screening
Karnofsky performance score of 60 or higher
Ability to sit and stand for at least 2 hours and swallow medications with an 8-ounce glass of water
Willing to use acceptable methods of contraception
Willing to adhere to study schedule

Exclusion Criteria:

Current cancers. Patients with basal cell carcinoma, in situ carcinoma of the cervix, or Kaposi's sarcoma without evidence of visceral involvement or cancer not requiring systemic chemotherapy are not excluded.
Severe premorbid psychiatric illness, including schizophrenia and major depression, which, in the opinion of the investigator, may interfere with the study
Active symptomatic AIDS-defining opportunistic infection within 45 days prior to study entry
Previous or current confounding neurological disorders. More information on this criterion can be found in the protocol.
Central nervous system infections or cancers. More information on this criterion can be found in the protocol.
Systemic lupus
Thyroid disease diagnosed within 24 weeks of study entry
Active drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study
Serious illness requiring systemic treatment or hospitalization. Patients who complete therapy or are clinically stable on therapy are not excluded.
Investigational agents within 45 days prior to study entry. Patients taking expanded access drugs or drugs used in an ACTG protocol for HIV treatment or for HIV-associated complications that are not prohibited by this protocol are not excluded.
History of allergy/sensitivity to minocycline or other tetracyclines and their formulations
Any esophageal or other condition that would interfere with a patient's ability to swallow study medication
Participation in a previous clinical drug research trial of HIV-associated cognitive impairment. Patients who have had an objective decline in performance as defined by the protocol are not excluded.
Any other clinically significant condition or laboratory abnormality that, in the opinion of the investigator, would interfere with the study
Certain medications
Certain abnormal laboratory values. Patients who test positive on nonreactive rapid plasma reagin tests (RPR)are not excluded.
Inability to undergo lumbar punctures
Breastfeeding